PapersFlow Research Brief
Gastrointestinal Tumor Research and Treatment
Research Guide
What is Gastrointestinal Tumor Research and Treatment?
Gastrointestinal Tumor Research and Treatment is the study of diagnosis, molecular characterization, classification, and therapies for tumors in the digestive system, including gastrointestinal stromal tumors (GISTs) and gastric adenocarcinomas, with emphasis on targeted agents like Imatinib Mesylate and Sunitinib, genetic mutations in KIT and PDGFRA, surgical management, and imaging techniques such as PET.
This field encompasses 53,643 published works on gastrointestinal tumors. Research covers GISTs, gastric cancers, and related adenocarcinomas, focusing on mutations, targeted therapies, and consensus diagnostic approaches. Key areas include the efficacy of Imatinib Mesylate in advanced GISTs and molecular profiling of gastric adenocarcinoma.
Topic Hierarchy
Research Sub-Topics
KIT Mutations Gastrointestinal Stromal Tumors
Research characterizes exon-specific KIT mutations driving GIST oncogenesis and their correlation with clinical phenotypes. Functional studies explore mutant KIT signaling and inhibitor sensitivity.
PDGFRA Mutations GIST
Studies focus on PDGFRA D842V resistance mutations and alternative primary mutations in KIT-wildtype GISTs. Research examines PDGFRA signaling pathways and novel inhibitors.
Imatinib Mesylate GIST Treatment
Clinical trials evaluate imatinib dosing, resistance mechanisms, and secondary mutations in advanced GIST. Pharmacokinetic studies optimize therapy duration and combination strategies.
Succinate Dehydrogenase Deficiency GIST
Research investigates SDH-deficient GIST subtypes, epigenetic modifications, and germline SDHx mutations. Studies develop SDHB immunohistochemistry for diagnosis and prognosis.
GIST Surgical Management
Guidelines address R0 resection principles, laparoscopic approaches, and multidisciplinary management of metastatic disease. Studies evaluate neoadjuvant imatinib impact on surgical outcomes.
Why It Matters
Gastrointestinal Tumor Research and Treatment directly impacts patient outcomes through targeted therapies and improved diagnostics. Demetri et al. (2002) demonstrated that Imatinib Mesylate induced a sustained objective response in more than half of patients with advanced unresectable or metastatic GISTs, establishing KIT inhibition as a standard treatment. Bang et al. (2010) showed in the ToGA trial that trastuzumab combined with chemotherapy improved survival in HER2-positive advanced gastric or gastro-oesophageal junction cancer compared to chemotherapy alone, with 7120 citations reflecting its clinical adoption. Janjigian et al. (2021) reported in the CheckMate 649 trial that first-line nivolumab plus chemotherapy outperformed chemotherapy alone for advanced gastric cancers, influencing first-line standards. These advances, alongside consensus guidelines like Fletcher et al. (2002) for GIST diagnosis, guide surgical and adjuvant strategies, reducing recurrence risks as seen in Macdonald et al. (2001) for post-surgical chemoradiotherapy in stomach adenocarcinoma.
Reading Guide
Where to Start
"Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors" by Demetri et al. (2002), as it provides foundational evidence on targeted therapy response rates in GISTs, accessible for understanding clinical impact without deep molecular prerequisites.
Key Papers Explained
Hirota et al. (1998) 'Gain-of-Function Mutations of c-kit in Human Gastrointestinal Stromal Tumors' discovered KIT mutations as the molecular driver of GISTs. Demetri et al. (2002) 'Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors' then validated KIT inhibition with Imatinib, achieving responses in over half of advanced cases. Fletcher et al. (2002) 'Diagnosis of gastrointestinal stromal tumors: A consensus approach' standardized diagnostics building on these findings. For gastric cancer, Bang et al. (2010) 'Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA)' extended targeted therapy to HER2-positive cases, while Bass et al. (2014) 'Comprehensive molecular characterization of gastric adenocarcinoma' mapped broader genomic alterations.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current efforts build on immunotherapy integration as in Janjigian et al. (2021) 'First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649)'. Focus persists on mutation-specific therapies for PDGFRA and SDH-deficient GISTs, PET response evaluation, and refining surgical consensus from papers like Bosman (2010) WHO Classification.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Trastuzumab in combination with chemotherapy versus chemothera... | 2010 | The Lancet | 7.1K | ✓ |
| 2 | Comprehensive molecular characterization of gastric adenocarci... | 2014 | Nature | 6.3K | ✓ |
| 3 | WHO Classification of Tumours of the Digestive System | 2010 | Medical Entomology and... | 4.8K | ✕ |
| 4 | Gastric cancer | 2020 | The Lancet | 4.5K | ✕ |
| 5 | Gain-of-Function Mutations of c- <i>kit</i> in Human Gastroint... | 1998 | Science | 4.4K | ✕ |
| 6 | Efficacy and Safety of Imatinib Mesylate in Advanced Gastroint... | 2002 | New England Journal of... | 4.3K | ✓ |
| 7 | Chemoradiotherapy after Surgery Compared with Surgery Alone fo... | 2001 | New England Journal of... | 3.5K | ✕ |
| 8 | Diagnosis of gastrointestinal stromal tumors: A consensus appr... | 2002 | Human Pathology | 3.4K | ✕ |
| 9 | Japanese classification of gastric carcinoma: 3rd English edition | 2011 | Gastric Cancer | 3.4K | ✓ |
| 10 | First-line nivolumab plus chemotherapy versus chemotherapy alo... | 2021 | The Lancet | 2.7K | ✓ |
Frequently Asked Questions
What is the role of KIT mutations in gastrointestinal stromal tumors?
Hirota et al. (1998) identified gain-of-function mutations of c-kit in human gastrointestinal stromal tumors through sequencing of c-kit complementary DNA from five GISTs. These mutations encode a proto-oncogenic receptor tyrosine kinase (KIT) central to GIST etiology. Targeting KIT with inhibitors like Imatinib addresses these mutations effectively.
How effective is Imatinib Mesylate for advanced GISTs?
Demetri et al. (2002) found that Imatinib Mesylate induced a sustained objective response in more than half of patients with advanced unresectable or metastatic gastrointestinal stromal tumors. Inhibition of the KIT signal-transduction pathway proved promising for tumors resistant to conventional treatments. This established Imatinib as a cornerstone therapy.
What does the ToGA trial show for HER2-positive gastric cancer?
Bang et al. (2010) conducted a phase 3 trial showing that trastuzumab in combination with chemotherapy improved outcomes over chemotherapy alone for HER2-positive advanced gastric or gastro-oesophageal junction cancer. The open-label, randomised controlled trial demonstrated superior efficacy. It set a benchmark for HER2-targeted therapy in gastric cancer.
What is the consensus approach for diagnosing GISTs?
Fletcher et al. (2002) outlined a consensus approach for diagnosing gastrointestinal stromal tumors in 'Diagnosis of gastrointestinal stromal tumors: A consensus approach'. It standardizes criteria based on pathology and molecular features. This aids accurate identification distinguishing GISTs from other mesenchymal tumors.
What are key prognostic factors in gastric cancer?
Macdonald et al. (2001) showed that postoperative chemoradiotherapy reduced recurrence in high-risk adenocarcinoma of the stomach or gastroesophageal junction patients post-resection. Smyth et al. (2020) reviewed gastric cancer management, highlighting staging and molecular factors. Classifications like Bosman (2010) in WHO Tumours of the Digestive System provide prognostic frameworks.
What recent advances exist in first-line therapy for advanced gastric cancer?
Janjigian et al. (2021) reported in CheckMate 649 that nivolumab plus chemotherapy improved survival versus chemotherapy alone in advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma. This phase 3 trial supports immunotherapy integration. It builds on prior targeted approaches like ToGA.
Open Research Questions
- ? How can SDH deficiency and PDGFRA mutations refine risk stratification beyond KIT in GISTs?
- ? What combinations of Imatinib, Sunitinib, and immunotherapy optimize outcomes in metastatic GISTs?
- ? How do molecular profiles from comprehensive characterization predict chemoradiotherapy response in gastric adenocarcinoma?
- ? What EUS-guided techniques and PET imaging metrics best evaluate early treatment response in gastrointestinal tumors?
- ? Which surgical margins and adjuvant strategies minimize recurrence in gastroesophageal junction adenocarcinomas?
Recent Trends
The field maintains focus on established targeted therapies like Imatinib Mesylate and emerging immunotherapy combinations as in Janjigian et al. CheckMate 649 trial with 2688 citations.
2021No new preprints or news in the last 6-12 months indicate steady consolidation of molecular diagnostics from Bass et al. and consensus approaches like Fletcher et al. (2002).
2014Growth data over 5 years is unavailable for the 53,643 works, but citation leaders from 1998-2021 underscore enduring impact of KIT-targeted advances.
Research Gastrointestinal Tumor Research and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Gastrointestinal Tumor Research and Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers